1352 - Clinical profile and patterns of progression (PD) of patients (pts) with advanced non-squamous non-small cell lung cancer (NSNSCLC) treated with fir...

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Metastatic
Presenter javier De Castro
Authors J. De Castro1, M. Domine2, J.M. Garcia-Bueno3, S. Saura4, R. Garcia-Gomez5, M. Sereno6, O. Juan7, E. Pujol8, B. Rubio9, M. Cobo10
  • 1Medical Oncology, Hospital Universitario La Paz, Madrid/ES
  • 2Oncology, Fundacion Jeminez DiazClin Nstra Senora de la Concepcion, ES-28040 - Madrid/ES
  • 3Oncology Deparment, Hospital General de Albacete, Albacete/ES
  • 4Medical Oncology, Hospital Universitario Dr. Negrin, Las Palmas de Gran Canaria/ES
  • 5Medical Oncology, Hospital General Universitario Gregorio Marañon, Madrid/ES
  • 6Medical Oncology, Hospital Infanta Sofia, Madrid/ES
  • 7Medical Oncology, Hospital Arnau de Vilanova, ES-46015 - Valencia/ES
  • 8Medical Oncology, Hospital Santa Barbara, Soria/ES
  • 9Medical Oncology, Centro Integral Oncológico Clara Campal, Madrid/ES
  • 10Medical Oncology, Hospital Regional Universitario Carlos Haya, Malaga/ES

Abstract

Background

B in combination with platinum doublets prolongs survival and delays PD in chemo-naïve pts with advanced nsNSCLC and its safety profile has been widely described in clinical trials. In this study we aim to evaluate the behavior, clinical profile and patterns of PD of real-life nsNSCLC pts treated with B in 44 Spanish institutions.

Methods

AVVA is a multicenter, epidemiological study to define the clinical profile (gender, age, PS, histology, stage, comorbidities, tumor load, Tx, response and tolerability) and describe the patterns of PD. Pts diagnosed with advanced nsNSCLC and evidence of PD after treatment (Tx) with standard chemotherapy (CT) plus B up to 6 cycles followed by maintenance B were included.

Results

Data of 158 pts are presented. Clinical profile was: median age 58 years (range 34-79); male 65%; stage IV 91%; adenocarcinoma 77%; ECOG PS 0/1/ ≥ 2 (%): 35/56/9; never/current/former smokers (%): 23/40/37. 64% of pts presented relevant concomitant disease at baseline (27% cardiovascular disease, 24% pulmonary disease). Tx received: B plus carboplatin-doublet/cisplatin-doublet/other (%) 70/25/5. Median no. of cycles for CT/B: 6/9. Patterns of PD: 44% presented high tumor load (tumor diameter ≥55mm and ≥5 lesions); 97% of pts presented intra-thoracic disease, 53% presented extra-thoracic disease and 13% only pulmonary disease. High tumor load was associated with extra-thoracic disease (p < 0.05). ORR was 53% (95% CI: 45-61) and disease control rate was 85%. Best response was achieved after a median of 4 cycles (range 1-16). ECOG 0/1 at PD (%): 15/50. Median PFS was 7.7 months (95% CI: 7.3-8.1). No differences were found in ORR or PFS according to tumor load and intra/extra-thoracic disease. Grade 3/4 toxicities were: venous thrombosis (3.2%/0), proteinuria (0.6%/0), hemoptysis (0.6%/0), pulmonary embolism (0/0.6%) and mucositis (0.6%/0).

Conclusions

B was effective in this real-life patients' population, irrespective of tumor load and location of the disease. These results confirm the well-established safety profile and the efficacy of B as frontline Tx in nsNSCLC.

Disclosure

All authors have declared no conflicts of interest.